David A Roth

US Patent:

7604995, Oct 20, 2009

Filed:

Jul 9, 2004

Appl. No.:

10/887593

Inventors:

David B. Roth - New York NY, US
Gregory S. Lee - New York NY, US

Assignee:

New York University - New York NY

International Classification:

C12N 15/87
C12N 15/00
C12N 15/64
C12P 19/34

US Classification:

435463, 435455, 435 914, 435 911

Abstract:

A method of stimulating homologous recombination by creating at least one nick in a targeted polynucleotide sequence. Wherein nonhomologous recombination is suppressed resulting in increasing the ratio of targeted to nontargeted events. A method of increasing double strand break-initiated gene targeting by inducing a nick in a targeted polynucleotide sequence, wherein overall recombination levels are increased. A method of increasing homologous recombination employing a recombinase that releases the ends in living cells by stimulating homolgous recombination to higher levels than those attainable with standard nucleases. A composition for stimulating homologous recombination including a nicking mechanism for creating nicks in a polynucleotide, wherein the nicking mechanism stimulates homologous recombination. A composition for stimulating homologous recombination including a nicking endonucleases. Various kits for stimulating homologous recombination.

US Patent:

20050154742, Jul 14, 2005

Filed:

Nov 24, 2004

Appl. No.:

10/996792

Inventors:

Aviv Roth - Brooklyn NY, US
David Roth - New York NY, US

International Classification:

G06F007/00

US Classification:

707100000

Abstract:

A business software application generation system and method are described.

US Patent:

20120174241, Jul 5, 2012

Filed:

Apr 22, 2011

Appl. No.:

13/066750

Inventors:

Ludovic Deriano - New York NY, US
David B. Roth - New York NY, US

International Classification:

A01K 67/027
C40B 30/04
G01N 21/64
G01N 33/53
C12N 5/10

US Classification:

800 10, 435 723, 435354, 435 611, 506 9

Abstract:

The invention provides mutant or transgenic animals and cells derived from the mutant or transgenic animals, and particularly a transgenic mouse, that is useful, among other things, for the study, prognosis and diagnosis of hematological malignancies, including T-cell acute lymphoblastic leukemia (T-ALL). Methods are provided for using the mouse model or mutant animal cells to assist in the discovery and identification of genes that may promote lymphomagenesis, to prognose and diagnose disease, and to screen for potential therapeutic agents or drugs.